ReviewClinical & developmental immunology2010
Vaccines and immunotherapeutics for the treatment of malignant disease.
Review in Clinical & developmental immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 39 citations in OpenAlex.
- Non-clinical safety evaluation of repeated intramuscular administration of the AS15 immunostimulant combined with various antigens in rabbits and cynomolgus monkeys.Journal of applied toxicology : JAT · 2016Trial
- Multi-disciplinary approaches paving the way for clinically effective peptide vaccines for cancer.NPJ vaccines · 2025Review
- Breast cancer immunotherapy: Realities and advances.Cancer innovation · 2024Review
- The Safety of an Adjuvanted Autologous Cancer Vaccine Platform in Canine Cancer Patients.Veterinary sciences · 2018Article
- A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2015Article
- Article
- Immunological aspects of radiotherapy.Radiation oncology (London, England) · 2014Article
- Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab.Human vaccines & immunotherapeutics · 2013Article
- The role of gamma interferon in DNA vaccine-induced tumor immunity targeting simian virus 40 large tumor antigen.Cancer immunology, immunotherapy : CII · 2013Article
- Combination immunotherapy with 4-1BBL and CTLA-4 blockade for the treatment of prostate cancer.Clinical & developmental immunology · 2012Article
- Relationship of therapeutic cancer vaccine development to population disease burden and five-year survival.Human vaccines · 2011Article
- Cancer vaccines.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2011Article
- Article
- CD4+ T lymphocytes are critical mediators of tumor immunity to simian virus 40 large tumor antigen induced by vaccination with plasmid DNA.Journal of virology · 2011Article
- Metastatic dormancy and progression in thyroid cancer: targeting cells in the metastatic frontier.Thyroid : official journal of the American Thyroid Association · 2011Review
- Production of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering.BioengineeredReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
The employment of the immune system to treat malignant disease represents an active area of biomedical research. The specificity of the immune response and potential for establishing long-term tumor immunity compels researchers to continue investigations into immunotherapeutic approaches for cancer. A number of immunotherapeutic strategies have arisen for the treatment of malignant disease, including various vaccination schemes, cytokine therapy, adoptive cellular therapy, and monoclonal antibody therapy. This paper describes each of these strategies and discusses some of the associated successes and limitations. Emphasis is placed on the integration of techniques to promote optimal scenarios for eliminating cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.